DBV Technologies S.A. (DBVT)
DBVT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$9.03
-5.45% on the day
Market cap
$534.7M
Small cap
Revenue · 2025
$5.6M
+35.8% on 2024
Net income · 2025
-$146.9M
-2607.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | DBVT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | France |
| IPO year | 2014 |
| SEC CIK | 0001613780 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | I0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.6M |
| Net income | -$146.9M |
| Operating income | -$147.1M |
| Net margin | -2607.3% |
| Operating margin | -2609.2% |
| Revenue growth | +35.8% |
| Cash | $194.2M |
| Total assets | $233.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 94.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-07-27 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-07-16 |
| Latest current report | 8-K | 2026-09-30 |
| Latest proxy | DEF 14A | 2026-05-11 |
Source: SEC EDGAR submissions feed, 574 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.3% |
| 1 month | -23.8% |
| 3 months | -39.7% |
| Year to date | -53.3% |
| 1 year | -45.4% |
| From 52-week high | -63.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ETRA | Electra Therapeutics Inc. | $8.61 | -7.62% | $540.4M |
| VALN | Valneva SE | $5.56 | -6.24% | $527.6M |
| RGNX | REGENXBIO Inc. | $7.26 | -6.56% | $479.3M |
| PRME | Prime Medicine Inc. | $3.32 | -8.03% | $602.2M |
| PROK | ProKidney Corp. | $1.57 | -5.99% | $474.6M |
| SLDB | Solid Biosciences Inc. | $5.82 | -13.26% | $624.1M |
| ALLO | Allogene Therapeutics Inc. | $1.29 | -7.86% | $445.7M |
| AURA | Aura Biosciences Inc. | $6.27 | -4.13% | $650.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier